Nessan Bermingham returns to VC life; Sanofi's generics unit gets two industry bidders in EMS and Torrent Pharma
→ Now that Intellia Therapeutics $INTL is sailing steadily toward its first human studies with AbbVie vet John Leonard at the helm, Nessan Bermingham will officially re-join Atlas Venture as a venture partner. Bermingham had been CEO of the Atlas-backed CRISPR/Cas-9 upstart (which he co-founded) for four years, leading the company from seed investment through an IPO to clinical development. Back in his venture capitalist shoes, he will be scouting for new biotechs for the Atlas platform.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.